Advertisement





Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2002; 39:1588-1593
© 2002 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aaberge, L.
Right arrow Articles by Forfang, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aaberge, L.
Right arrow Articles by Forfang, K.

CLINICAL STUDY: RANSMYOCARDIAL REVASCULARIZATION

Continued symptomatic improvement three to five years after transmyocardial revascularization with co2 laser

A late clinical follow-up of the norwegian randomized trial with transmyocardial revascularization

Lars Aaberge, MD*,*, Kjell Rootwelt, MD, PhD{dagger}, Svein Blomhoff, MD, PhD{ddagger}, Kjell Saatvedt, MD, PhD§, Michel Abdelnoor, MPH, PhD|| and Kolbjorn Forfang, MD, PhD*

* Department of Cardiology, Rikshospitalet University Hospital, Oslo, Norway
{dagger} Department of Clinical Chemistry/Section of Nuclear Medicine, Rikshospitalet University Hospital, Oslo, Norway
{ddagger} Department of Psychiatry, Rikshospitalet University Hospital, Oslo, Norway
§ Feiringklinikken, Feiring, Oslo, Norway
|| Ullevaal University Hospital, Oslo, Norway

Manuscript received October 15, 2001; revised manuscript received February 21, 2002, accepted February 22, 2002.

* Reprint requests and correspondence: Dr. Lars Aaberge, Feiringklinikken, N-2093 Feiring, Norway.
laaaberg{at}online.no

OBJECTIVES: The goals of this study were to assess late clinical outcome and left ventricular ejection fraction (LVEF) after transmyocardial revascularization with CO2 laser (TMR).

BACKGROUND: During the 1990s TMR emerged as a treatment option for patients with refractory angina not eligible for conventional revascularization. Few reports exist on clinical effects and LVEF >3 years after TMR.

METHODS: One hundred patients with refractory angina not eligible for conventional revascularization were block-randomized 1:1 to receive continued medical treatment or medical treatment combined with TMR. The patients were evaluated at baseline and after 3, 12 and 43 (range: 32 to 60) months with end points to angina, hospitalizations due to acute myocardial infarctions or unstable angina, heart failure and LVEF. Mortality was registered and MOS 36 Short-Form Health Survey answered at baseline and after 3, 6 and 12 months.

RESULTS: Forty-three months after TMR, angina symptoms were still significantly improved, and unstable angina hospitalizations reduced by 55% (p < 0.001). Heart failure treatment (p < 0.01) increased, whereas the number of acute myocardial infarctions, LVEF and mortality was not affected. Quality of life was improved 3, 6 and 12 months after TMR.

CONCLUSIONS: Forty-three months after TMR, angina symptoms and hospitalizations due to unstable angina were significantly reduced, heart failure treatment increased and LVEF and mortality were seemingly unaffected.

Abbreviations and Acronyms
  DSE
  dobutamine stress echocardiography
  LVEF
  left ventricular ejection fraction
  MCS
  summary mental component scale
  MT
  medical treatment
  MUGA
  multiple-gated acquisition
  NYHA
  New York Heart Association
  OBL
  baseline outcome variable
  OFU
  follow-up outcome variable
  PCS
  summary physical component scale
  QoL
  quality of life
  SF-36
  MOS 36 Short-Form Health Survey
  SPECT
  technetium 99m-tetrofosmin myocardial perfusion scan
  TMR
  transmyocardial revascularization with CO2 laser




This article has been cited by other articles:


Home page
Card Surg AdultHome page
K. A. Horvath and Y. Zhou
Transmyocardial Laser Revascularization and Extravascular Angiogenetic Techniques to Increase Myocardial Blood Flow
Card. Surg. Adult, January 1, 2008; 3(2008): 733 - 752.
[Full Text]


Home page
J Am Coll CardiolHome page
S. Banai, S. Ben Muvhar, K. H. Parikh, A. Medina, H. Sievert, A. Seth, J. Tsehori, Y. Paz, A. Sheinfeld, and G. Keren
Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility first-in-man study.
J. Am. Coll. Cardiol., May 1, 2007; 49(17): 1783 - 1789.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
D. McNab, S. N. Khan, L. D. Sharples, J. Y. Ryan, C. Freeman, N. Caine, S. Tait, I. Hardy, and P. M. Schofield
An open label, single-centre, randomized trial of spinal cord stimulation vs. percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the SPiRiT trial
Eur. Heart J., May 1, 2006; 27(9): 1048 - 1053.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. E. Nordrehaug and M. Salem
Treatment of chronic refractory angina pectoris--light at the end of the tunnel?
Eur. Heart J., May 1, 2006; 27(9): 1007 - 1009.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
G. S. Allen
Mid-Term Results After Thoracoscopic Transmyocardial Laser Revascularization
Ann. Thorac. Surg., August 1, 2005; 80(2): 553 - 558.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
K. B. Allen, R. D. Dowling, and W. Richenbacher
Reply.
Ann. Thorac. Surg., June 1, 2005; 79(6): 2200 - 2201.
[Full Text] [PDF]


Home page
ICVTSHome page
A. Sanni and J. Dunning
Is transmyocardial revascularisation of benefit to people with 'no option' angina?
Interactive CardioVascular and Thoracic Surgery, December 1, 2004; 3(4): 586 - 592.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
S. K. Mouli, J. Fronza, R. Greene, E. S. Robert, and K. A. Horvath
What is the Optimal Channel Density for Transmyocardial Laser Revascularization?
Ann. Thorac. Surg., October 1, 2004; 78(4): 1326 - 1331.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
K. B. Allen, R. D. Dowling, D. R. Schuch, T. A. Pfeffer, S. Marra, E. A. Lefrak, T. L. Fudge, M. Mostovych, S. Szentpetery, S. P. Saha, et al.
Adjunctive transmyocardial revascularization: five-year follow-up of a prospective, randomized trial
Ann. Thorac. Surg., August 1, 2004; 78(2): 458 - 465.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
K. B. Allen, R. D. Dowling, W. W. Angell, D. M. Gangahar, T. L. Fudge, W. Richenbacher, S. L. Selinger, M. R. Petracek, and D. Murphy
Transmyocardial revascularization: 5-year follow-up of a prospective, randomized multicenter trial
Ann. Thorac. Surg., April 1, 2004; 77(4): 1228 - 1234.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
C. R. Bridges, K. A. Horvath, W. C. Nugent, D. M. Shahian, C. K. Haan, R. J. Shemin, K. B. Allen, and F. H. Edwards
The Society of Thoracic Surgeons practice guideline series: transmyocardial laser revascularization
Ann. Thorac. Surg., April 1, 2004; 77(4): 1494 - 1502.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement